



TO STUDY THE EFFECTIVENESS OF COGNITIVE BEHAVIORAL THERAPY (CBT) ON FATIGUE IN PATIENTS OF SYSTEMIC LUPUS ERYTHEMATOSUS AT IGMC, SHIMLA

¹Sharma A, ²Garg M

¹ Junior Resident, ² Junior Resident

¹ Psychiatry Department,

¹ Indira Gandhi Medical College, Shimla, Himachal Pradesh, India

Abstract: Introduction: Systemic lupus erythematosus (SLE) is an autoimmune disease, with multisystemic involvement. Symptoms may manifest over a wide spectrum, with varying clinical presentations. Of the various systems which can be affected by SLE, one of the more common yet relatively unexplored system is the central nervous system. NPSLE which involves the central nervous system (CNS), peripheral nervous system (PNS) and autonomous nervous system (ANS) is one of the most complex and challenging manifestations of SLE. The most common symptoms of NPSLE include mild cognitive dysfunction, mood disorders, anxiety, headaches, and psychosis. Aim: To study the effectiveness of Cognitive Behavioral Therapy (CBT) on neuropsychiatric manifestations in patients of SLE. Results: Fatigue as assessed by Modified Fatigue Impact Scale (MFIS) was 32.4 ± 4.6 in the treatment arm at the post intervention as compared to 40.9 ± 6.00 in the standard arm at the post intervention ($p < 0.001$). MFIS score showed improvement in patients with symptoms of fatigue who received CBT as per MFIS scale (from 41.6 ± 5.8 to 32.4 ± 4.6). Conclusion: CBT improves fatigue as represented by MFIS scores. Thus, CBT or CBT-based interventions can be used with the pharmacological treatment of the SLE patients.

Index Terms - CBT, Fatigue, NPSLE, MFIS

I. INTRODUCTION

Systemic lupus erythematosus (SLE) is an autoimmune disease with a relapsing-remitting course.^{1,2} NPSLE is one of the most complex and challenging manifestations of SLE, which involves the central nervous system (CNS), peripheral nervous system (PNS) and autonomous nervous system (ANS). The pathogenesis of Neuropsychiatric manifestations of SLE (NPSLE) is multifactorial. Two major pathways proposed for explaining the pathogenesis in NPSLE are an ischaemic pathway involving large and small blood vessels and second mechanism is an autoimmune-mediated neuroinflammatory pathway with complement activation which is associated with most diffuse neuropsychiatric manifestations such as psychosis, mood disorders, cognitive dysfunction and acute confusional states.³⁻⁷ The utilization of CBT for managing and ameliorating psychiatric manifestations of NPSLE has been explored recently. Randomised controlled trials (RCTs) have found that CBT is associated with a significant reduction in the level of depression, anxiety and daily stress

and a significant improvement in Quality of Life (QoL) and somatic symptoms throughout the entire follow-up period.^{8,9} Management protocols usually centre around long-term patient survival, maintaining an acceptable quality-of-life, and preventing relapses as much as possible.² The present study was done to assess the effectiveness of CBT on fatigue in patients of SLE.

II. RESEARCH METHODOLOGY

It was a single-blinded randomized clinical trial study conducted at Indira Gandhi Medical College and Hospital, Shimla. Patients of SLE, fulfilling 2019 EULAR/ACR (European League Against Rheumatism/American College of Rheumatology) classification criterion for SLE and clinically stable for last 3 months attending Rheumatology Department from November 2020 to December 2021 were recruited into the study. A total of 40 patients were included after applying inclusion and exclusion criteria and they were divided into 2 groups (Control and CBT), each group containing 20 patients.

Inclusion criteria: Patients with age more than 18 years and up to 60 years and who give their consent to participate in the study.

Exclusion criteria: Subjects with acute confusional state, severe cognitive impairment, alcohol use disorder and other substance use disorders, chronic liver disease, chronic kidney disease, chronic viral infections like Hepatitis B, Hepatitis C, pregnancy, cerebrovascular accidents, coronary artery disease, malignancies and other intracranial disorders, persons who are unable to read and write in Hindi or English and suffering from severe psychiatric disorder.

III. RESULTS AND DISCUSSION

Results:

A total of 40 patients who fulfilled inclusion criteria were recruited in the study after obtaining the informed consent. They were divided into Control and CBT group, each group containing 20 patients. The median MFIS value in 40 patients was 41.0 (37.0, 44.2). There was no statistically significant difference between the median values of MFIS total score in CBT group at 42.0 (36.8, 45.5) and that of control group at 41.0 (38.8, 44.0) ($p=0.8$) at baseline. After CBT intervention, the median MFIS value in 40 patients was 35.5 (31.5, 41.0). There was statistically significant difference between the median values of MFIS total score in CBT group at 31.0 (29.0, 34.2) and that of control group at 40.0 (36.0, 43.5) ($p<0.001$).

Table 1: MFIS scoring at baseline

Characteristic	N = 40 ¹
MFIS-Total-Baseline	
Median, (IQR))	41.0, (37.0, 44.2))
Range	32.0, 53.0
Mean (SD)	41.4 (5.1)
¹ n (%)	

Table 2: MFIS scoring at baseline in groups

Characteristic	CBT, N = 20 ¹	CONTROL, N = 20 ¹	p-value ²
MFIS-Total-Baseline			0.8
Median, (IQR))	42.0, (36.8, 45.5))	41.0, (38.8, 44.0))	
Range	32.0, 53.0	34.0, 51.0	
Mean (SD)	41.6 (5.8)	41.2 (4.4)	
¹ n (%)			
² Fisher's exact test; Wilcoxon rank sum test			




Figure 1: The median MFIS value in 40 patients was 41.0 (37.0, 44.2). There was no statistically significant difference between the median values of MFIS total score in CBT group at 42.0 (36.8, 45.5) and that of control group at 41.0 (38.8, 44.0) (p=0.8)

Table 3: Post intervention MFIS

Characteristic	N = 40 ¹
MFIS-Total-post intervention	
Median, (IQR))	35.5, (31.5, 41.0))
Range	28.0, 56.0
Mean (SD)	36.6 (6.8)
¹ n (%)	

Table 4: Post intervention MFIS in groups

Characteristic	CBT, N = 20 ¹	CONTROL, N = 20 ¹	p-value ²
MFIS-Total-post intervention			<0.001
Median, (IQR))	31.0, (29.0, 34.2))	40.0, (36.0, 43.5))	
Range	28.0, 48.0	33.0, 56.0	
Mean (SD)	32.4 (4.6)	40.9 (6.0)	
¹ n (%)			
² Fisher's exact test; Wilcoxon rank sum test			




Figure 2: The median MFIS value in 40 patients was 35.5 (31.5, 41.0) There was statistically significant difference between the median values of MFIS total score in CBT group at 31.0 (29.0, 34.2) and that of control group at 40.0 (36.0, 43.5) ($p < 0.001$).

Discussion:

The present study was a single-blinded randomized clinical study conducted in the Department of Psychiatry at Indira Gandhi Medical College and Hospital, Shimla. Effect of CBT on fatigue in patients of SLE was assessed. Pre- and post-intervention assessment of MFIS scores was conducted on both the groups and compared to understand the improvement of fatigue due to CBT intervention in SLE patients.

Fatigue is highly prevalent in SLE patients. In the index study, we found that although there was no significant difference in fatigue scores (as measured by the MFIS tool) between the intervention and control group at the baseline, post intervention the intervention group had a significantly lower fatigue score as compared to the control group (32.40 ± 4.6 in the intervention group; 40.9 ± 6.00 in the control group ($p < 0.001$). Mean difference in MFIS score between two groups showed significant improvement from baseline ($p = 0.001$). Our findings are similar to studies that has shown that CBT has been found to have reduced fatigue in patients with long term, physical health conditions.¹⁰ CBT is effective in reducing fatigue in patients of multiple sclerosis also.¹¹

CBT has shown to improve mental health of patients. MFIS scores showed significant improvement in fatigue with CBT. Thus, it can be said that CBT or CBT-based interventions can be used with the pharmacological treatment of the SLE patients.

IV. ACKNOWLEDGEMENT

I take great pleasure in expressing my profound gratitude and heartfelt thanks to all those who have helped me in the successful accomplishment of this study. I am highly indebted to my colleagues whose endless support helped me throughout my study. My whole hearted thanks to my patients for their patience and help in my study.

V. REFERENCES

1. Shaikh MF, Jordan N, D'Cruz DP. Systemic lupus erythematosus. *Clin Med (Lond)*. 2017 Feb 1;17(1):78–83
2. Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update on the diagnosis and management of systemic lupus erythematosus. *Ann Rheum Dis*. 2021 Jan;80(1):14–25.
3. Moore E, Huang MW, Putterman C. Advances in the diagnosis, pathogenesis and treatment of neuropsychiatric systemic lupus erythematosus. *Curr Opin Rheumatol*. 2020 Mar 1;32(2):152–8.
4. Schwartz N, Stock AD, Putterman C. Neuropsychiatric lupus: new mechanistic insights and future treatment directions. *Nat Rev Rheumatol*. 2019 Mar 1;15(3):137–52.
5. Jeltsch-David H, Muller S. Neuropsychiatric systemic lupus erythematosus: pathogenesis and biomarkers. *Nat Rev Neurol*. 2014 Jan 1;10(10):579–96.
6. Hanly JG, Kozora E, Beyea SD, Birnbaum J. Review: Nervous System Disease in Systemic Lupus Erythematosus: Current Status and Future Directions. *Arthritis Rheumatol*. 2019 Jan 1;71(1):33–42.
7. Govoni M, Bortoluzzi A, Padovan M, Silvagni E, Borrelli M, Donelli F et al. The diagnosis and clinical management of the neuropsychiatric manifestations of lupus. *J Autoimmun*. 2016 Nov 1;74:41–72.
8. Navarrete-Navarrete N, Peralta-Ramírez MI, Sabio-Sánchez JM, Coín MA, RoblesOrtega H, Hidalgo-Tenorio C et al. Efficacy of cognitive behavioural therapy for the treatment of chronic stress in patients with lupus erythematosus: a randomized controlled trial. *Psychother Psychosom*. 2010 Feb;79(2):107–15.

9. Solati K, Mousavi M, Kheiri S, Hasanpour-Dehkordi A. The Effectiveness of Mindfulness-based Cognitive Therapy on Psychological Symptoms and Quality of Life in Systemic Lupus Erythematosus Patients: A Randomized Controlled Trial. *Oman Medical Journal*. 2017 Sep 1;32(5):378.
10. Hulme K, Safari R, Thomas S, Mercer T, White C, Linden M vander et al. Fatigue interventions in long term, physical health conditions: A scoping review of systematic reviews. *PLoS One*. 2018 Oct 1;13(10): e0203367.
11. van Kessel K, Moss-Morris R, Willoughby E, Chalder T, Johnson MH, Robinson E. A randomized controlled trial of cognitive behavior therapy for multiple sclerosis fatigue. *Psychosom Med*. 2008 Feb;70(2):205–13.

